Abu Dhabi Doctors Pioneer CAR-T Therapy for Rare Autoimmune Case
Abu Dhabi has achieved a major medical milestone with the successful use of CAR-T cell therapy to treat a complex autoimmune condition. In a groundbreaking case, the Abu Dhabi Stem Cells Center (ADSCC), in collaboration with Yas Clinic Khalifa City, administered CAR-T therapy to a 38-year-old man suffering from severe systemic lupus erythematosus (SLE) and triple-positive antiphospholipid syndrome (APS).
This marks one of the earliest applications of CAR-T therapy for autoimmune diseases in the Middle East, highlighting the UAEās leadership in advanced healthcare innovation.
A Complex and High-Risk Patient
The patient had a long history of severe complications, including diffuse alveolar haemorrhage, recurrent brain bleeding, deep vein thrombosis, pulmonary embolism, IVC thrombosis, and Budd-Chiari syndrome. Despite being treated with multiple immunosuppressants and anticoagulants, his disease activity remained uncontrolled and life-threatening.
Given the complexity of his case, traditional treatments had reached their limits. After careful evaluation, doctors decided to try CAR-T therapy, a revolutionary immune-modulating approach originally developed for cancer patients but now being tested globally for autoimmune conditions.
What is CAR-T Therapy?
Chimeric Antigen Receptor T-cell (CAR-T) therapy involves reprogramming a patientās own immune cells to fight disease. In cancer, CAR-T has been highly successful in treating blood cancers like leukemia and lymphoma. Now, researchers are exploring its potential in autoimmune diseases, where the immune system attacks the bodyās own tissues.
By āresettingā the immune system, CAR-T therapy may offer long-term remission for patients who have exhausted all other treatment options.
Early Signs of Recovery
Following the procedure, the patient began showing early signs of improvement and what doctors describe as an āimmune reset.ā He has since been discharged from the hospital and is being monitored under a comprehensive follow-up plan to track his remission status and manage clotting risks.
Prof. Yendry Ventura, CEO of ADSCC, called the treatment āa bold step forward in managing severe autoimmune conditions,ā adding that it reflects years of investment in research, innovation, and patient-focused care.
Dr. Maysoon Al Karam, Chief Medical Officer at Yas Clinic Khalifa City, described the achievement as āa transformative milestone in regional healthcare,ā noting that the partnership between ADSCC and Yas Clinic Khalifa City is setting new standards for autoimmune disease treatment.
Strengthening the UAEās Position in Healthcare Innovation
The successful case highlights Abu Dhabiās growing reputation as a hub for advanced therapies and regenerative medicine. It reflects the UAEās broader national strategy to position itself as a global leader in medical innovation.
ADSCC has already achieved several firsts in the region. In 2020, it launched the UAEās first comprehensive bone marrow transplant program, offering life-saving treatment to patients with blood cancers and immune disorders. The center also operates the countryās only fully integrated stem cell collection, processing, and clinical care facility.
In 2024, ADSCCās cellular therapy processing laboratory received accreditation from the Foundation for the Accreditation of Cellular Therapy (FACT)āa first for the UAE and one of only two such facilities in the entire region. This accreditation places the center among the worldās most advanced institutions for cellular therapies.
Looking Ahead: New Hope for Autoimmune Patients
Globally, CAR-T therapy is still in the trial phase for autoimmune diseases. However, this Abu Dhabi case signals a turning point for patients in the region suffering from severe, treatment-resistant conditions such as lupus, APS, and other autoimmune disorders.
While more studies and long-term monitoring are needed, the successful use of CAR-T therapy in this case offers new hope to patients who have run out of conventional options. It also shows that the UAE is not just adopting cutting-edge medical technologies but actively pioneering their use in new fields.
For ADSCC and Yas Clinic Khalifa City, the achievement is more than just a medical breakthrough. It represents a commitment to improving patient outcomes, training the next generation of specialists, and advancing Abu Dhabiās position as a global center for innovation in healthcare.
Conclusion
The first successful application of CAR-T therapy for autoimmune disease in the Middle East is a testament to the UAEās commitment to transformative healthcare solutions. By combining advanced research, international standards, and patient-centered care, Abu Dhabi is shaping the future of regenerative medicine and offering new possibilities for patients once considered untreatable.
Related News
